Titleist Asset Management LLC Has $242,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Titleist Asset Management LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 6.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,815 shares of the company’s stock after selling 208 shares during the quarter. Titleist Asset Management LLC’s holdings in Novo Nordisk A/S were worth $242,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. GQG Partners LLC raised its position in Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Folketrygdfondet raised its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after purchasing an additional 40,313 shares during the last quarter. Sustainable Growth Advisers LP lifted its position in shares of Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after purchasing an additional 1,021,498 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $404,910,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the topic of several recent analyst reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Up 1.5 %

Shares of NYSE NVO opened at $63.52 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $285.03 billion, a PE ratio of 19.31, a P/E/G ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a one year low of $60.61 and a one year high of $148.15. The business’s fifty day moving average price is $80.37 and its 200-day moving average price is $95.75.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.